Evaxion begins experimental testing of two AI-Immunology autoimmune treatment concepts

Reuters2026/09/14 12:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evaxion expanded its AI-Immunology platform into autoimmune diseases, testing two new treatment concepts in experimental studies.
Initial results have not been presented yet; the company plans to present experimental data on November 18, 2026 at PEGS Europe.
The programs aim to target underlying disease drivers, seeking improved efficacy with fewer side effects than current symptom-focused therapies.
Management framed the move as a strategic expansion into a high unmet-need area with partnership potential across drug development stages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED1001262521) on September 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evaxion begins experimental testing of two AI-Immunology autoimmune treatment concepts

You may also like

Crypto prices